Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
about
MPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesThe Cell Killing Mechanisms of HydroxyureaTargeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy.A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.Genetic basis of MPN: Beyond JAK2-V617F.Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials.Novel Cell-Killing Mechanisms of Hydroxyurea and the Implication Towards Combination Therapy for the Treatment of Fungal Infections.Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea.Mycobacterium avium Auricular Infection in an Apparent Immunocompetent Patient: A Case Report.Hydroxyurea Induces Cytokinesis Arrest in Cells Expressing a Mutated Sterol-14α-Demethylase in the Ergosterol Biosynthesis PathwayInterferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.Heme deficiency sensitizes yeast cells to oxidative stress induced by hydroxyurea.Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.MicroNIR/Chemometrics Assessement of Occupational Exposure to Hydroxyurea.
P2860
Q26775996-18309C42-C410-4A74-BAB0-C24CB978F49FQ28080250-F1879B37-D215-49E4-9EC9-13E7C18D4DCEQ36353167-0EC34F78-FB3B-4317-B7F4-94760F84B19EQ37955231-6633037D-DBD1-4482-B2C8-9F1A6628BDF6Q38159973-08FBD1FD-813D-424B-BD6C-CE54DBCFBB47Q38187674-6828835E-54CE-4718-AB75-DA442D4FDD4CQ38420817-F349F78A-2399-4493-AC54-31160E4DF318Q38586505-33DBCBC6-0C7C-41E9-BF91-FFDF1B66473AQ39979643-79FE0DB4-7146-4F95-AD2E-A1EDDA33D8A4Q40052683-0FEF489A-149C-4C7B-B2C4-C73F20BC585CQ40240400-5F5D5FA6-F5C3-4796-8ACF-F2269181FF72Q40566031-836725E3-F39D-4B4E-A07D-613AC0E8DC69Q42741306-B5AAB9A2-A4C3-4AC1-8538-73E0A0A3B472Q46636672-AB132B38-80E2-486F-873F-4BB170B606E2Q47699454-75887D54-1D9F-4D40-AB6D-9B0CBEFA2041Q51071426-250F2259-E3C2-4F00-8035-DEADD41B9388Q51608068-B58C7901-BCC5-45E7-A601-7FF2C1170BFBQ55422014-B8785B8A-9EA4-4208-A659-A3D8130C6C36
P2860
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@ast
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@en
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@nl
type
label
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@ast
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@en
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@nl
prefLabel
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@ast
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@en
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
@nl
P2860
P356
P1476
Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders
@en
P2093
Jerry L Spivak
P2860
P304
P356
10.1586/ERA.11.10
P577
2011-03-01T00:00:00Z